Factors predicting HER-2/neu overexpression in primary operable breast cancers (n = 1362): univariate analysis
| HER-2/neu expression* | Odds ratio† | p Value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| Data are number of patients (%). | ||||
| *HER-2/neu was defined as negative when the DAKO score was 0, 1+, or 2+ and positive when 3+; †odds ratio adjusted for all variables in table; ‡ER and PR were defined as negative when the H score was ⩽50, and positive when 51–300. | ||||
| ER, oestrogen receptor; PR, progesterone receptor. | ||||
| ER status‡ | ||||
| Negative | 184 (71.3%) | 74 (28.7%) | 5.52 | <0.001 |
| Positive | 1029 (93.2%) | 75 (6.8%) | 1 | |
| PR status‡ | ||||
| Negative | 391 (80.1%) | 97 (19.9%) | 3.92 | <0.001 |
| Positive | 822 (94.1%) | 52 (5.9%) | 1 | |
| Tumour grade | ||||
| 1–2 | 790 (95.4%) | 38 (4.6%) | 1 | <0.001 |
| 3 | 423 (79.2%) | 111 (20.8%) | 5.46 | |
| Tumour size | ||||
| ⩽20 mm | 645 (89.5%) | 76 (10.5%) | 1 | 0.617 |
| >20 mm | 568 (88.6%) | 73 (11.4%) | 1.09 | |
| Lymph node | ||||
| Negative | 790 (89.8%) | 90 (10.2%) | 1 | 0.255 |
| Positive | 423 (87.8%) | 59 (12.2%) | 1.22 | |
| Age | ||||
| ⩽50 years | 377 (87.9%) | 52 (12.1%) | 1.19 | 0.344 |
| >50 years | 836 (89.6%) | 97 (10.4%) | 1 | |